Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | GAA | P10253 | 3/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | YAP1 | P46937 | 1/20 | 0.58 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GPR183 | P32249 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818267 | 1.00 | TSHR (1.00) | TSHRLMNAKMT2AMEN1MAPT | |
| SCHEMBL4814829 | 0.90 | LMNA (1.00) | TSHRLMNAKMT2AMEN1MAPT | |
| SCHEMBL4814836 | 0.90 | LMNA (1.00) | TSHRLMNAKMT2AMEN1MAPT | |
| SCHEMBL18864671 | 0.83 | TSHR (0.71) | TSHRLMNAKMT2AMEN1MAPT | |
| SCHEMBL18864669 | 0.83 | TSHR (0.71) | TSHRLMNAKMT2AMEN1MAPT | |
| SCHEMBL7222883 | 0.83 | TSHR (0.71) | TSHRLMNAKMT2AMEN1MAPT | |
| SCHEMBL18864777 | 0.83 | TSHR (0.71) | TSHRLMNAKMT2AMEN1MAPT | |
| SCHEMBL13202849 | 0.82 | TSHR (0.69) | TSHRLMNAKMT2AMEN1MAPT | |
| SCHEMBL30047393 | 0.81 | TSHR (0.69) | TSHRLMNAKMT2AMEN1MAPT | |
| SCHEMBL21593709 | 0.81 | TSHR (0.69) | TSHRLMNAKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342020-B2 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2008-03-11 | — | — | US | disclosed |
| EP-1109787-B1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
| US-6734184-B1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171641-A1 | Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) | MMP13, MMP25, MMP3 | TSHR 2604/4885LMNA 3582/4885KMT2A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.